Hypersound Medical, a medical technology innovator developing non-invasive, ultrasound-based therapies for chronic and acute pain, announced it has been placed on the National Science Foundation (NSF) Fast-Track program, accelerating the company’s path toward Medicare coverage while pursuing FDA clearance for its breakthrough non-invasive pain therapy device.
The advancement follows the device’s designation as a Non-Significant Risk (NSR) medical device. As a result, Hypersound is able to move quickly into clinical validation and reimbursement readiness in parallel.
Hypersound’s precision ultrasound platform delivers targeted nerve stimulation without drugs, needles, or surgery, addressing the gap between low-power TENS units and costly implantable neurostimulators.
“This NSF Fast-Track recognition validates our science and shortens our path to patients,” said Tim Dickman, CEO & President of Hypersound Medical. “It allows us to advance regulatory and coverage milestones simultaneously. This is an uncommon and welcome advantage for emerging medical technologies.”
To learn more about the Hypersound technology, contact info@hypersoundmedical.com.
The NSF Fast-Track program is a pilot initiative within the National Science Foundation’s (NSF) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs (also known as America’s Seed Fund). It allows eligible small businesses and startups to submit a single, combined proposal for both Phase I and Phase II funding, offering a potentially faster path to commercialization than the traditional two-step process.